Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide Pharmacokinetics Interaction Study with Digoxin in Healthy Adults
NCT06597760Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Infinity up to 5 days. Started Oct 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06597760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597760.